← 홈

CGT · 다발성 골수종

135개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-14 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 135개
CGTCHotBiologicstaleThomas Martin, MDPhase 1

Chimeric Antigen Receptor T cells (CAR-T, Chimeric Antigen Receptor T cells, Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA)

Multiple Myeloma; Recurrent Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#인기#세포유전치료+5
효능 ORR 97.1%임상시험 113상태 DISCONTINUED
CGTABiologicNational Cancer Institute (NCI)inPhase 1

Anti-B Cell Maturation Antigen (BCMA, Anti-B Cell Maturation Antigen, Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells)

Myeloma-Multiple; Myeloma, Plasma-Cell · BCMA

#BCMA#CGT#Phase1#인기#세포유전치료+5
효능 ORR 97.1%임상시험 73상태 RECRUITING
CGTBiologicMalaysia Palm Oil BoardPhase 1

Interleukin (Interleukin)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase1#인기#세포유전치료+3
효능 ORR 2%임상시험 60상태 ACTIVE
CGTBiologicCelgenevedotin (BV) maintenance th…Phase 2

ASCT (ASCT)

Multiple Myeloma; Newly Diagnosed · Multiple Myeloma

#MultipleMyeloma#CGT#Phase2#인기#세포유전치료+5
효능 ORR 11%임상시험 59상태 RECRUITING
CGTBiologicMinsk Scientific-Practical Cent…Phase 2

Anti-BCMA CAR-T cells (Anti-BCMA CAR-T cells)

Multiple Myeloma Refractory · BCMA

#BCMA#CGT#Phase2#인기#세포유전치료+5
효능 ORR 97.1%임상시험 56상태 RECRUITING
CGTBiologicCarbiogene Therapeutics Co. Ltd.Phase 1

anti-BCMA CAR-T (anti-BCMA CAR-T)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#인기#세포유전치료+5
효능 ORR 97.1%임상시험 55상태 ACTIVE
CGTBiologicInternational Brain Research Fo…Phase 2

Quercetin (Quercetin)

Recurrent Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase2#인기#세포유전치료+5
임상시험 54상태 RECRUITING
CGTBiologicPoseida Therapeutics, Inc.Phase 2

autologous anti-BCMA chimeric antigen receptor T cells (autologous anti-BCMA chimeric antigen receptor T cells)

ITP · BCMA

#BCMA#CGT#Phase2#세포유전치료#CAR-T+4
효능 ORR 97.1%임상시험 47상태 ACTIVE
CGTBiologicMerck Sharp & Dohme LLCPhase 2

Letermovir (Letermovir)

Relapsed Refractory Multiple Myeloma (RRMM) · Cell Therapy

#CellTherapy#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 45상태 RECRUITING
CGTBiologicSung-Soo ParkPreclinical

IMiD treatment (IMiD treatment)

Multiple Myeloma, Relapsed; Multiple Myeloma (MM) · FRα

#FR#CGT#Preclinical#세포유전치료#CAR-T+5
효능 ORR 48.3%임상시험 39상태 RECRUITING
CGTBiologicBristol-Myers SquibbPhase 2

bb2121 (Ide-cel, Ide-cel (bb2121))

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase2#세포유전치료#CAR-T+3
효능 ORR 74.5%임상시험 33상태 RECRUITING
CGTBiologicBeijing BiotechPhase 2

AP1903 (AP1903)

Leukemia; Myeloma · Sarcoma

#Sarcoma#CGT#Phase2#세포유전치료#CAR-T+5
효능 ORR 2%임상시험 32상태 RECRUITING
CGTBiologicChinese PLA General HospitalPhase 2

Anti-BCMA-CD19 CAR-T cells (Anti-BCMA-CD19 CAR-T cells)

IgG4 Related Disease; B-cell Mediated Autoimmune Disorders · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 30상태 RECRUITING
CGTBiologicstaleNanjing Legend Biotech Co.Phase 2

LCAR-B38M CAR-T Cell (LCAR-B38M CAR-T Cell)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase2#세포유전치료#CAR-T+2
효능 ORR 96.6%임상시험 22상태 DISCONTINUED
CGTBiologicstalePersonGen BioTherapeutics (Suzh…Phase 1

T cell infusion agent targeting BCMA chimeric antigen receptor (T cell infusion agent targeting BCMA chimeric antigen receptor)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+3
효능 ORR 42.9%임상시험 13상태 ACTIVE
CGTBiologicstaleAsclepius Technology Company Gr…Phase 1

Anti-BCMA CAR-NK Cells (Anti-BCMA CAR-NK Cells)

Multiple Myeloma, Refractory · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 10상태 ACTIVE
CGTBiologicstaleNanjing IASO Biotechnology Co.,…Phase 2

Eque-cel (Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection, Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (Eque-cel))

Relapsed/Refractory Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 9상태 RECRUITING
CGTBiologicstaleShanghai AbelZeta Ltd.Phase 1

C-CAR088 (C-CAR088)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 6상태 ACTIVE
CGTBiologicstaleiCell Gene TherapeuticsPhase 1

BCMA-CD19 cCAR T cells (BCMA-CD19 cCAR T cells)

Relapsed/Refractory, Systemic Lupus Erythematosus (SLE) · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 5상태 RECRUITING
CGTBiologicYake Biotechnology Ltd.Phase 1

APRIL CAR-T cells (APRIL CAR-T cells)

Multiple Myeloma in Relapse; Multiple Myeloma, Refractory · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 4상태 RECRUITING

1 / 7 페이지

← 이전다음 →